Etoposide phosphate

Drug Profile

Etoposide phosphate

Alternative Names: BMY 40481; Etopofos; Etopophos

Latest Information Update: 18 Jan 2008

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antineoplastics; Tetrahydronaphthalenes
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Small cell lung cancer; Testicular cancer
  • Discontinued Cancer

Most Recent Events

  • 02 Oct 2001 No-Development-Reported for Cancer (PO)
  • 28 Sep 2001 This compound is still in active development
  • 15 Nov 1997 Investigation in Small cell lung cancer in Europe (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top